Instil Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $46.8M
- Price
- $6.90
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.22%
- Volume
- 7.3K
About
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Quick stats
Shares outstanding6.8M
Computed float4.0M
Float / shares59.4%
Cash runway (months)41.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001789769
Websitehttps://instilbio.com
AI Summary
AI-generated1/8
standardmixedearnings
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio reported a cash position of $69.9 million as of June 30, 2026, which management expects to fund the current operating plan into 2028.
Internal development activities have effectively ceased, with in-process R&D expenses dropping to zero and total R&D spending falling approximately 90% year-over-year to $0.3 million.
The company is now actively evaluating potential acquisitions and in-licensing opportunities to identify new therapeutic candidates.
Red flags
- In-process R&D expenses were nil for Q2 2026
- R&D expenses dropped over 90% year-over-year
- Company pivot to M&A/in-licensing due to lack of internal pipeline progress